about
sameAs
PGC-1α, a potential therapeutic target for early intervention in Parkinson's diseaseConcomitant pathologies among a spectrum of parkinsonian disordersKnowledge gaps and research recommendations for essential tremor.Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.Research priorities in spasmodic dysphoniaEvaluation of alpha-synuclein immunohistochemical methods used by invited expertsClinicopathological outcomes of prospectively followed normal elderly brain bank volunteers.Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathologyPET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.The neurobiological basis of cognitive impairment in Parkinson's disease.Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease.Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders.Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body DisordersCervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy)Autonomic complaints in patients with restless legs syndrome.Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry.Sleep issues in Parkinson's disease.Low clinical diagnostic accuracy of early vs advanced Parkinson disease: clinicopathologic studyRationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia?Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinationsIncidental Lewy body disease: clinical comparison to a control cohort.No evidence for cognitive dysfunction or depression in patients with mild restless legs syndrome.Nonmotor complications in Parkinson's disease.MDS clinical diagnostic criteria for Parkinson's disease.MDS research criteria for prodromal Parkinson's disease.Relevance of motor complications in Parkinson's disease.Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions.Essential tremor and Parkinson's disease: lack of a linkPatient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variabilityHeterogeneous neuropathological findings in Parkinson's disease with mild cognitive impairment.Neuropathological findings of PSP in the elderly without clinical PSP: possible incidental PSP?SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndromeParkinson's disease, cortical dysfunction, and alpha-synuclein.Incidental Lewy body disease: electrophysiological findings suggesting pre-clinical Lewy body disordersClinical features, with video documentation, of the original familial lewy body parkinsonism caused by α-synuclein triplication (Iowa kindred).MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.Biochemical increase in phosphorylated alpha-synuclein precedes histopathology of Lewy-type synucleinopathies
P50
Q24597726-074A3E29-E77C-4EAE-A426-0881C01D83F4Q28236077-DF703029-E17A-40F5-92DA-08EB009C4511Q30244228-02D2C9A1-2642-47C1-913A-C97E31009DF6Q30278084-9BFE5253-0527-402D-A1BF-A80FA000BE7CQ30486026-25FFDF0D-7FE0-498B-9D17-3FF9AE1C9430Q30488694-1790F278-1829-4D66-8452-83FF44D46C53Q33456273-E050EA61-9476-4032-8C4B-9E5DC3B559E8Q33567669-8A11AE7E-5DF9-4D7B-AAFD-CE7484DDD414Q33637285-E9437F84-C6E7-40C0-9F9F-8FD2B1D5F69BQ33724698-054483E1-403F-4C60-B583-DDB4385CE7BCQ33767351-9AA93546-6F90-4EE1-A7D6-5BEB547FD4E2Q33835599-D21A27DC-38F0-4027-8F6E-D5A1774CBB9DQ33874572-38B30CCD-C18B-4671-8AB5-B24E74023C67Q33901413-9CA07F0A-CB9B-441D-8FC3-D5EEE193416FQ33927057-45664EA6-5347-4D7A-B4E3-CD48595D0688Q33935711-A7CECF51-2872-4F90-8A51-79714C1C9731Q33988295-A8993D98-350E-4543-BA0A-6667949E4A57Q34043770-81317543-CCA1-4707-842F-3C983DE9C1CBQ34067456-494C9571-731F-472A-A125-783CE4DF8CD6Q34083307-21CD744E-DEB5-489C-A611-8EEDEB7C3F3DQ34084369-85DB7041-4F81-4C12-89C9-2DBAA1ACAD5DQ34111184-05990C02-654E-4BFD-A36D-CD907FD7FCF8Q34111348-62D65787-D740-4121-A420-3957012B4ABAQ34410401-F8107A35-CE17-4F87-AAB7-07CA4EDC5076Q34498274-3C068A52-FB05-41B1-AA57-EC7B13A2EB9EQ34498279-A0D7EF2D-C500-44D2-9D9E-BC39FA3AA973Q34574617-DDAB302F-4D8F-40AF-9044-349BCB346689Q34583449-43779563-32CA-4A9C-A54C-155780C65978Q34743030-E25D1ABB-61C5-4304-BC36-BCCC39AEA072Q34762107-E2F6CBB0-7D4A-4FC9-8A2E-6C15AD2878EEQ34774765-452B4F7A-45D0-46F6-A7DD-A7BD49E2E484Q35002066-2B719DE0-F71B-496B-A50D-8CC059757F0FQ35028155-B0C017DA-8FAB-445B-9BD3-F800CF7CEEC2Q35035515-AE11AC09-80F4-461C-B557-6867D20316B9Q35059012-015B7E17-26B7-491E-862B-FCF8C6C27913Q35161124-245C2651-37F4-449F-978A-DE7A91AE1F62Q35190139-3CC28F13-A8E4-458F-A297-A146F49635D2Q35207288-5410DE20-BBE5-48EA-B6DB-96CBEAD56BC0Q35234522-ADA73D69-F5AD-4980-82AD-8E49790BD718Q35593764-6E397F73-C83A-4AD8-B986-A7CDA3598C40
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Charles H Adler
@ast
Charles H Adler
@en
Charles H Adler
@es
Charles H Adler
@nl
تشارلز إتش أدلر
@ar
type
label
Charles H Adler
@ast
Charles H Adler
@en
Charles H Adler
@es
Charles H Adler
@nl
تشارلز إتش أدلر
@ar
altLabel
Adler CH
@en
C H Adler
@en
Charles Adler
@ast
Charles Adler
@en
Charles Adler
@nl
prefLabel
Charles H Adler
@ast
Charles H Adler
@en
Charles H Adler
@es
Charles H Adler
@nl
تشارلز إتش أدلر
@ar
P214
P106
P214
P31
P4012
P496
0000-0002-1045-2743
P734
P735
P7859
lccn-n00120363